ARCHIVES

Sanofi: Zaltrap Price Reflects Competing Drugs In Second-Line Metastatic Colon Cancer

This article is from The Cancer Letter archive.

Vol. 38 No. 41 | November 1, 2012

Download PDF Visit The Full Archive

Related Articles

Cyclamate Review Committee Starts Survey; Inventor Castigates NCI

September 12, 1975

NCI Bypass Budget Seeks $3.6 Billion for Fiscal 1995

October 1, 1993

Most of NCI’s $60 Million Increase In FY95 will fund Mandatory Raise In Prevention

October 14, 1994

Panel Urges Research On DCIS To Identify Women At High Risk For Invasive Cancer

September 25, 2009

Conferees Stalled On Money Bill, Running Out Of Time

September 17, 1976

In Brief: Durant New President Of AACI, Ultmann Named President-Elect; Farber Center Gets New Name

February 4, 1983